Lexaria Bioscience receives groundbreaking U.S. patent allowance for its DehydraTECH delivery of THC, NSAIDs, Nicotine, and Vitamins.
Lexaria Bioscience Corp., a drug delivery platform company, has received a new Notice of Allowance from the United States Patent and Trademark Office (USPTO) for the use of its technology as a delivery platform for all cannabinoids including tetrahydrocannabinol (THC); fat soluble vitamins; non steroidal anti-inflammatory pain medications (NSAIDs); and nicotine.
The Notice of Allowance applies to the delivery of all active pharmacological ingredients (APIs) Lexaria had been seeking. The allowance for the broad API applicability is significantly ahead of expectations, according to the company. As with the company’s existing non-psychoactive cannabinoid patent that was granted in 2016, Lexaria expects formal patent issuance within three to four months, which is expected to provide protection until at least 2035.
Under USPTO practice, there is no opposition period between allowance and issuance. The patent application number is 15/225,799, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.”
Lexaria said it also continues to advance all of its additional patent applications in various countries, adding that one of its patent applications has recently entered the active patent investigation phase in China.
“Issuance of this broad patent will give Lexaria the ability to ramp up our technology out-licensing activities especially within the pharmaceutical sector, where the expanded API capacity of our DehydraTECH delivery platform will be most applicable,” said John Docherty, president.
Lexaria’s patented DehydraTECH technology is focused on improved delivery methodologies of many commonly used API substances. As such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. Both patented and generic API substances can utilize Lexaria’s patented technology. Lexaria said its long-term strategy is to partner with firms as they deliver products to their existing large consumer groups.
(Source: Lexaria Bioscience Corp.)
